NEWTON, Mass.--(BUSINESS WIRE)--Axena Health, Inc. (Axena Health), a medical device company focused on female pelvic health, today announced the appointment of Randy Pritchard as its new Chief Executive Officer, effective immediately. Pritchard brings nearly 25 years of experience in medical device and health technology, including leadership in driving commercial success, innovation, and strategic opportunities. His extensive background will be critical in advancing Axena Health’s mission to improve the lives of women affected by pelvic floor disorders such as urinary incontinence (UI) and fecal incontinence (FI).
Pritchard joins Axena Health with a proven track record in strategic leadership and business expansion. He most recently served as CEO of Pillar Biosciences, a sequencing diagnostics company supporting cancer patients, where he led daily operations, secured funding, and drove top and bottom-line performance. Pritchard’s prior leadership at Roche Diagnostics, where he held key roles as Senior Vice President of Marketing, further highlights his ability to launch disruptive new technologies and implement strategies that boost customer satisfaction and increase sales.
As CEO of Axena Health, Pritchard will oversee the company’s operations and growth strategy, focusing on expanding access to the company’s flagship product, the Leva® Pelvic Health System. The Leva System offers a non-invasive, medication-free solution for treating UI and FI, addressing critical gaps in the women’s health space. Under Pritchard’s leadership, Axena Health will continue building partnerships, raising capital to support growth, and executing on its vision to provide evidence-based, at-home, first-line treatments for female pelvic floor disorders.
Shacey Petrovic, Board Member at Axena Health, added: "Randy has a strong history of leading innovative companies and delivering meaningful healthcare solutions. His proven ability to execute growth strategies and build a mission-driven culture aligns perfectly with Axena Health’s vision of changing the standard of care for female pelvic floor disorders."
"We are excited to have Randy Pritchard leading Axena Health into its next phase of growth," said Bret Christensen, Chairman of the Board at Axena Health. "Randy’s commercial acumen, operational expertise, and passion for improving patient outcomes make him the ideal leader to take Axena Health forward as we broaden access to its transformative pelvic health treatments for women."
In his new role, Pritchard will focus on refining the company’s strategic direction, improving insurance coverage for the Leva System, and driving operations across all functional areas, including sales and marketing and market access. He will also lead efforts to expand strategic partnerships within the women’s health space, while continuing to position the Leva System as the only prescription, at-home, first-line treatment for female UI and FI.
"I am thrilled to join Axena Health at this pivotal time," said Randy Pritchard. "The company’s mission to transform women’s health with innovative, non-invasive treatments deeply resonates with me. I look forward to working with the company’s talented team to scale the business, continue product innovation, and improve access to effective solutions for pelvic floor disorders."
About the Leva® Pelvic Health System
The Leva® Pelvic Health System offers an innovative, non-invasive, medication-free way for women to train and strengthen their pelvic floor muscles—at home in just five minutes a day—to treat urinary incontinence (UI) and chronic fecal incontinence (FI). Combining a small FDA-cleared vaginal motion sensor with integrated software, the Leva System offers precise visualization of pelvic movement in real-time, enables progress tracking and allows active physician involvement, all of which support women’s success. Recognizing that level-one evidence shows pelvic floor muscle training is most effective when performed under the supervision of a skilled healthcare provider, the Leva System is available by prescription only, allowing physicians the opportunity to treat UI and chronic FI on a broad scale and with continued involvement in patient success. The Leva System has multiple clinical trials and published data from globally recognized medical centers supporting its efficacy in treating UI, including two studies in Obstetrics and Gynecology (The Green Journal), the official publication of the American College of Obstetricians and Gynecologists (ACOG).
About Axena Health
Axena Health, Inc. is dedicated to improving the lives of women with pelvic floor disorders. Axena Health’s flagship product, the Leva® Pelvic Health System, offers a novel, effective, first-line treatment for urinary incontinence (UI) and chronic fecal incontinence (FI), underreported conditions affecting over 78 million and 12 million women in the U.S. alone. Axena Health's technology enables non-invasive, drug-free treatment via precise visualization of movement in real time during pelvic floor muscle training, while monitoring usage and progress. For more information, please visit www.axenahealth.com or www.levatherapy.com and follow Axena Health on LinkedIn.
Important Indication and Other Information for the Leva® Pelvic Health System
The Leva® Pelvic Health System is intended for (1) strengthening of pelvic floor muscles, (2) rehabilitation and training of weak pelvic floor muscles for the treatment of stress, mixed, and mild to moderate urgency urinary incontinence (including overactive bladder) in women and (3) rehabilitation and training of weak pelvic floor muscles for the first-line treatment of chronic fecal incontinence (>3-month uncontrolled passage of feces) in women. Treatment with the Leva System is by prescription and is not for everyone. Please talk to your prescriber to see if Leva System is right for you. Your prescriber should discuss all potential benefits and risks with you. Do not use Leva System while pregnant, or if you think you may be pregnant, unless authorized by your doctor. For a complete summary of the risks and instructions for the Leva System, see its Instructions for Use available at www.levatherapy.com.
